Oramed Pharmaceuticals Inc. (NASDAQ:ORMP - Get Free Report) passed below its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $2.29 and traded as low as $2.24. Oramed Pharmaceuticals shares last traded at $2.26, with a volume of 124,880 shares.
Analyst Ratings Changes
Separately, Wall Street Zen lowered Oramed Pharmaceuticals from a "hold" rating to a "sell" rating in a research note on Saturday, May 17th.
Check Out Our Latest Stock Report on Oramed Pharmaceuticals
Oramed Pharmaceuticals Stock Performance
The firm has a market capitalization of $87.83 million, a P/E ratio of 19.55 and a beta of 1.65. The business has a 50 day simple moving average of $2.21 and a two-hundred day simple moving average of $2.29.
Oramed Pharmaceuticals (NASDAQ:ORMP - Get Free Report) last posted its quarterly earnings data on Thursday, May 15th. The biotechnology company reported ($0.19) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.03) by ($0.16). The firm had revenue of $2.00 million during the quarter. On average, equities analysts anticipate that Oramed Pharmaceuticals Inc. will post -0.03 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Oramed Pharmaceuticals
Several institutional investors have recently bought and sold shares of ORMP. N.E.W. Advisory Services LLC boosted its holdings in Oramed Pharmaceuticals by 52.9% during the 1st quarter. N.E.W. Advisory Services LLC now owns 18,900 shares of the biotechnology company's stock valued at $40,000 after acquiring an additional 6,540 shares during the period. World Equity Group Inc. purchased a new stake in Oramed Pharmaceuticals during the 4th quarter valued at about $48,000. Jane Street Group LLC lifted its holdings in Oramed Pharmaceuticals by 35.3% in the 1st quarter. Jane Street Group LLC now owns 67,173 shares of the biotechnology company's stock worth $144,000 after buying an additional 17,510 shares during the period. Dimensional Fund Advisors LP lifted its holdings in Oramed Pharmaceuticals by 143.8% in the 4th quarter. Dimensional Fund Advisors LP now owns 118,995 shares of the biotechnology company's stock worth $288,000 after buying an additional 70,190 shares during the period. Finally, Peapod Lane Capital LLC lifted its holdings in Oramed Pharmaceuticals by 11.0% in the 1st quarter. Peapod Lane Capital LLC now owns 252,224 shares of the biotechnology company's stock worth $540,000 after buying an additional 24,985 shares during the period. 12.73% of the stock is currently owned by hedge funds and other institutional investors.
Oramed Pharmaceuticals Company Profile
(
Get Free Report)
Oramed Pharmaceuticals Inc engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes.
See Also
Before you consider Oramed Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Oramed Pharmaceuticals wasn't on the list.
While Oramed Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
